Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

ImmunityBio (IBRX) Long-Term Debt Issuances: 2020-2024

Historic Long-Term Debt Issuances for ImmunityBio (IBRX) over the last 1 years, with Jun 2024 value amounting to $97.0 million.

  • ImmunityBio's Long-Term Debt Issuances rose 224.81% to $97.0 million in Q2 2024 from the same period last year, while for Jun 2024 it was $355.7 million, marking a year-over-year increase of 52.10%. This contributed to the annual value of $97.0 million for FY2024, which is 62.52% down from last year.
  • Latest data reveals that ImmunityBio reported Long-Term Debt Issuances of $97.0 million as of Q2 2024, which was down 51.28% from $199.0 million recorded in Q3 2023.
  • In the past 5 years, ImmunityBio's Long-Term Debt Issuances ranged from a high of $298.5 million in Q4 2021 and a low of $29.9 million during Q1 2023.
  • Moreover, its 3-year median value for Long-Term Debt Issuances was $73.4 million (2022), whereas its average is $88.3 million.
  • In the last 5 years, ImmunityBio's Long-Term Debt Issuances slumped by 83.33% in 2022 and then skyrocketed by 224.81% in 2024.
  • ImmunityBio's Long-Term Debt Issuances (Quarterly) stood at $63.7 million in 2020, then reached $298.5 million in 2021, then crashed by 83.33% to $49.8 million in 2022, then surged by 60.00% to $199.0 million in 2023, then soared by 224.81% to $97.0 million in 2024.
  • Its Long-Term Debt Issuances was $97.0 million in Q2 2024, compared to $199.0 million in Q3 2023 and $29.9 million in Q2 2023.